BOSTON (AP) - Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies find that it does not improve survival ...
Avastin-Tarceva combination improved progression-free survival in advanced gallbladder cancer and cholangiocarcinoma compared to active surveillance. The study reported a median PFS of 5.3 months for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results